Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis

E. G. Dorsey-Treviño, J. G. González-González, N. Alvarez-Villalobos, V. González-Nava, B. M. Contreras-Garza, A. Díaz González-Colmenero, G. Rodríguez-Tamez, F. J. Barrera-Flores, A. M. Farrell, V. M. Montori, R. Rodriguez-Gutierrez

Research output: Contribution to journalArticle

Abstract

Purpose: The effect of the sodium-glucose 2 (SGLT-2) inhibitors on microvascular complications remains uncertain. We performed a systematic review to determine the efficacy of the SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes. Methods: A comprehensive search was performed using Ovid, MEDLINE, EMBASE, Web of Science, and Scopus from inception to May 2019. Randomized trials comparing SGLT-2 inhibitors with placebo or other medication for type 2 diabetes for ≥ 4 weeks were included. Diabetes-related microvascular complications such as nephropathy, retinopathy, neuropathy, and peripheral vascular disease were evaluated. A random-effect model using mean differences for continuous outcomes and risk ratio for dichotomous outcomes was used to synthesize data. PROSPERO (CRD 42017076460). Results: A total of 40 RCTs with overall moderate quality of evidence were included. SGLT-2 inhibitors reduced the risk of renal-replacement therapy (0.65; 95% CI 0.54–0.79), renal death (0.57; 95% CI 0.49–0.65), and progression of albuminuria (0.69; 95% CI 0.66–0.73). Conversely, they appeared ineffective in maintaining eGFR (0.33; 95% CI − 0.74 to 1.41) or reducing serum creatinine (− 0.07; 95% CI − 0.26 to 0.11), whereas urine albumin–creatinine ratio (− 23.4; 95% CI − 44.6 to − 2.2) was reduced. Risk of amputation was non-significant (1.30; 95% CI 0.93–1.83). No available data were found regarding neuropathy and retinopathy to perform a quantitative analysis. Conclusion: SGLT-2 inhibitors may reduce the risk of renal patient-important outcomes but fail to improve surrogate outcomes. Apparently, no increased risk of amputations was observed with these medications. No data were available regarding other microvascular complications.

Original languageEnglish (US)
JournalJournal of endocrinological investigation
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Sodium-Glucose Transport Proteins
Type 2 Diabetes Mellitus
Meta-Analysis
Amputation
Kidney
Albuminuria
Renal Replacement Therapy
Peripheral Vascular Diseases
Diabetes Complications
MEDLINE
Creatinine
Sodium
Odds Ratio
Placebos
Urine
Glucose
Serum

Keywords

  • Meta-analysis
  • Microvascular complications
  • Sodium-glucose cotransporter 2 inhibitors
  • Systematic review
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Dorsey-Treviño, E. G., González-González, J. G., Alvarez-Villalobos, N., González-Nava, V., Contreras-Garza, B. M., Díaz González-Colmenero, A., ... Rodriguez-Gutierrez, R. (Accepted/In press). Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis. Journal of endocrinological investigation. https://doi.org/10.1007/s40618-019-01103-9

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes : systematic review and meta-analysis. / Dorsey-Treviño, E. G.; González-González, J. G.; Alvarez-Villalobos, N.; González-Nava, V.; Contreras-Garza, B. M.; Díaz González-Colmenero, A.; Rodríguez-Tamez, G.; Barrera-Flores, F. J.; Farrell, A. M.; Montori, V. M.; Rodriguez-Gutierrez, R.

In: Journal of endocrinological investigation, 01.01.2019.

Research output: Contribution to journalArticle

Dorsey-Treviño, EG, González-González, JG, Alvarez-Villalobos, N, González-Nava, V, Contreras-Garza, BM, Díaz González-Colmenero, A, Rodríguez-Tamez, G, Barrera-Flores, FJ, Farrell, AM, Montori, VM & Rodriguez-Gutierrez, R 2019, 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis', Journal of endocrinological investigation. https://doi.org/10.1007/s40618-019-01103-9
Dorsey-Treviño EG, González-González JG, Alvarez-Villalobos N, González-Nava V, Contreras-Garza BM, Díaz González-Colmenero A et al. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis. Journal of endocrinological investigation. 2019 Jan 1. https://doi.org/10.1007/s40618-019-01103-9
Dorsey-Treviño, E. G. ; González-González, J. G. ; Alvarez-Villalobos, N. ; González-Nava, V. ; Contreras-Garza, B. M. ; Díaz González-Colmenero, A. ; Rodríguez-Tamez, G. ; Barrera-Flores, F. J. ; Farrell, A. M. ; Montori, V. M. ; Rodriguez-Gutierrez, R. / Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes : systematic review and meta-analysis. In: Journal of endocrinological investigation. 2019.
@article{3c89f9ff38814e9aa8f1239d0769eed0,
title = "Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis",
abstract = "Purpose: The effect of the sodium-glucose 2 (SGLT-2) inhibitors on microvascular complications remains uncertain. We performed a systematic review to determine the efficacy of the SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes. Methods: A comprehensive search was performed using Ovid, MEDLINE, EMBASE, Web of Science, and Scopus from inception to May 2019. Randomized trials comparing SGLT-2 inhibitors with placebo or other medication for type 2 diabetes for ≥ 4 weeks were included. Diabetes-related microvascular complications such as nephropathy, retinopathy, neuropathy, and peripheral vascular disease were evaluated. A random-effect model using mean differences for continuous outcomes and risk ratio for dichotomous outcomes was used to synthesize data. PROSPERO (CRD 42017076460). Results: A total of 40 RCTs with overall moderate quality of evidence were included. SGLT-2 inhibitors reduced the risk of renal-replacement therapy (0.65; 95{\%} CI 0.54–0.79), renal death (0.57; 95{\%} CI 0.49–0.65), and progression of albuminuria (0.69; 95{\%} CI 0.66–0.73). Conversely, they appeared ineffective in maintaining eGFR (0.33; 95{\%} CI − 0.74 to 1.41) or reducing serum creatinine (− 0.07; 95{\%} CI − 0.26 to 0.11), whereas urine albumin–creatinine ratio (− 23.4; 95{\%} CI − 44.6 to − 2.2) was reduced. Risk of amputation was non-significant (1.30; 95{\%} CI 0.93–1.83). No available data were found regarding neuropathy and retinopathy to perform a quantitative analysis. Conclusion: SGLT-2 inhibitors may reduce the risk of renal patient-important outcomes but fail to improve surrogate outcomes. Apparently, no increased risk of amputations was observed with these medications. No data were available regarding other microvascular complications.",
keywords = "Meta-analysis, Microvascular complications, Sodium-glucose cotransporter 2 inhibitors, Systematic review, Type 2 diabetes mellitus",
author = "Dorsey-Trevi{\~n}o, {E. G.} and Gonz{\'a}lez-Gonz{\'a}lez, {J. G.} and N. Alvarez-Villalobos and V. Gonz{\'a}lez-Nava and Contreras-Garza, {B. M.} and {D{\'i}az Gonz{\'a}lez-Colmenero}, A. and G. Rodr{\'i}guez-Tamez and Barrera-Flores, {F. J.} and Farrell, {A. M.} and Montori, {V. M.} and R. Rodriguez-Gutierrez",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s40618-019-01103-9",
language = "English (US)",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Editrice Kurtis s.r.l.",

}

TY - JOUR

T1 - Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes

T2 - systematic review and meta-analysis

AU - Dorsey-Treviño, E. G.

AU - González-González, J. G.

AU - Alvarez-Villalobos, N.

AU - González-Nava, V.

AU - Contreras-Garza, B. M.

AU - Díaz González-Colmenero, A.

AU - Rodríguez-Tamez, G.

AU - Barrera-Flores, F. J.

AU - Farrell, A. M.

AU - Montori, V. M.

AU - Rodriguez-Gutierrez, R.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: The effect of the sodium-glucose 2 (SGLT-2) inhibitors on microvascular complications remains uncertain. We performed a systematic review to determine the efficacy of the SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes. Methods: A comprehensive search was performed using Ovid, MEDLINE, EMBASE, Web of Science, and Scopus from inception to May 2019. Randomized trials comparing SGLT-2 inhibitors with placebo or other medication for type 2 diabetes for ≥ 4 weeks were included. Diabetes-related microvascular complications such as nephropathy, retinopathy, neuropathy, and peripheral vascular disease were evaluated. A random-effect model using mean differences for continuous outcomes and risk ratio for dichotomous outcomes was used to synthesize data. PROSPERO (CRD 42017076460). Results: A total of 40 RCTs with overall moderate quality of evidence were included. SGLT-2 inhibitors reduced the risk of renal-replacement therapy (0.65; 95% CI 0.54–0.79), renal death (0.57; 95% CI 0.49–0.65), and progression of albuminuria (0.69; 95% CI 0.66–0.73). Conversely, they appeared ineffective in maintaining eGFR (0.33; 95% CI − 0.74 to 1.41) or reducing serum creatinine (− 0.07; 95% CI − 0.26 to 0.11), whereas urine albumin–creatinine ratio (− 23.4; 95% CI − 44.6 to − 2.2) was reduced. Risk of amputation was non-significant (1.30; 95% CI 0.93–1.83). No available data were found regarding neuropathy and retinopathy to perform a quantitative analysis. Conclusion: SGLT-2 inhibitors may reduce the risk of renal patient-important outcomes but fail to improve surrogate outcomes. Apparently, no increased risk of amputations was observed with these medications. No data were available regarding other microvascular complications.

AB - Purpose: The effect of the sodium-glucose 2 (SGLT-2) inhibitors on microvascular complications remains uncertain. We performed a systematic review to determine the efficacy of the SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes. Methods: A comprehensive search was performed using Ovid, MEDLINE, EMBASE, Web of Science, and Scopus from inception to May 2019. Randomized trials comparing SGLT-2 inhibitors with placebo or other medication for type 2 diabetes for ≥ 4 weeks were included. Diabetes-related microvascular complications such as nephropathy, retinopathy, neuropathy, and peripheral vascular disease were evaluated. A random-effect model using mean differences for continuous outcomes and risk ratio for dichotomous outcomes was used to synthesize data. PROSPERO (CRD 42017076460). Results: A total of 40 RCTs with overall moderate quality of evidence were included. SGLT-2 inhibitors reduced the risk of renal-replacement therapy (0.65; 95% CI 0.54–0.79), renal death (0.57; 95% CI 0.49–0.65), and progression of albuminuria (0.69; 95% CI 0.66–0.73). Conversely, they appeared ineffective in maintaining eGFR (0.33; 95% CI − 0.74 to 1.41) or reducing serum creatinine (− 0.07; 95% CI − 0.26 to 0.11), whereas urine albumin–creatinine ratio (− 23.4; 95% CI − 44.6 to − 2.2) was reduced. Risk of amputation was non-significant (1.30; 95% CI 0.93–1.83). No available data were found regarding neuropathy and retinopathy to perform a quantitative analysis. Conclusion: SGLT-2 inhibitors may reduce the risk of renal patient-important outcomes but fail to improve surrogate outcomes. Apparently, no increased risk of amputations was observed with these medications. No data were available regarding other microvascular complications.

KW - Meta-analysis

KW - Microvascular complications

KW - Sodium-glucose cotransporter 2 inhibitors

KW - Systematic review

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85073776386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073776386&partnerID=8YFLogxK

U2 - 10.1007/s40618-019-01103-9

DO - 10.1007/s40618-019-01103-9

M3 - Article

C2 - 31489568

AN - SCOPUS:85073776386

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

ER -